

2019-06

# National prospective observational study of inpatient management of adults with epistaxis a National Trainee Research Collaborative delivered investigation

Mehta, N

<http://hdl.handle.net/10026.1/14207>

---

10.4193/rhin18.239

Rhinology journal

Rhinology

---

*All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.*

National prospective observational study of inpatient management of  
adults with epistaxis – a National Trainee Research Collaborative  
delivered investigation

Single group author: INTEGRATE (please see contributor list for exact contributions from  
each researcher, including the author committee)

Corresponding author: Nishchay Mehta BSc PhD MBBS DOHNS FRCS (ORL-HNS), Ear  
Institute, UCL, 332 Gray's Inn Road, London WC1X 8DA, 00447863545576,  
[nishchay.mehta.12@ucl.ac.uk](mailto:nishchay.mehta.12@ucl.ac.uk)

Funding: ENTUK and British Rhinological Society

Original article

Word count: 2968 words excluding references and abstract

## Key points

- This is the largest study of the in-hospital management of epistaxis
- Nasal cautery at the time of first specialist ENT review reduces treatment time by more than half, even after controlling for patient age, disease severity and whether patient was packed or not prior to ENT review.
- Patients who receive a treatment algorithm that follows national guidance are 87% more likely to achieve haemostasis before patients who do not.
- The 30-day hospital readmission rate is not affected by treatments that reduce treatment time.

## Abstract

**Importance:** There is a paucity of high quality evidence relating to the management of epistaxis severe enough to require admission to a hospital. Previous studies of interventions for epistaxis have suffered from small sample sizes. They lacked the power to allow analysis of the effect of an intervention on epistaxis control that is independent of the condition severity or additional interventions given.

**Objective:** To determine the effect of specialist treatments on the successful management of severe epistaxis

**Design:** Secondary analysis of data collected from a national multi-centre audit of patients with epistaxis over 30 days in 2016. Data were entered prospectively, and patients were followed up for 30 days following hospital discharge.

**Setting:** 113 participating UK hospitals.

**Participants:** 1402 adults admitted for inpatient management of epistaxis were identified, with data entered prospectively during the 30-day audit window.

**Exposure:** Exposure variables assessed included treatment instigated at first ENT review, intervention strategy during hospitalization, disease factors (e.g. severity), patient risk

factors (e.g. co-morbidities, medications) and treatment factors (grade of doctor, therapies initiated during hospital stay).

Main Outcomes: Treatment time (time from first ENT review to time haemostasis was achieved and patient was safe for hospital discharge). 30-day hospital readmission rate.

Results: 834 patients had sufficient data for inclusion. Patients who did not receive nasal cautery at first specialist review had a treatment time greater than double the time of those who were cauterised: Adjusted ratio (aR) 2.5 (95% CI 1.7-3.3), after controlling for age, bleeding severity, and whether they received a nasal pack or not. Only 30% of patients received management that complied with new national guidance, but those that did were 87% more likely to be achieve haemostasis before those that did not, even after controlling for bleeding severity. Type of treatment, whether initial intervention or management strategy, did not affect 30-day re-attendance.

Conclusions and Relevance: Analysis of national audit data suggest that cautery at first specialist review, and management according to national guidance can reduce hospital treatment times without compromising 30-day re-attendance. Future work should investigate why early nasal cautery is infrequently used, and how service delivery can be optimised to allow widespread implementation of evidence-based management for epistaxis.

## Introduction

Epistaxis is common, with a lifelong incidence of 60% in the general population(1). Most episodes of epistaxis are self-limiting, and only rarely is emergency medical treatment required when the bleeding becomes heavy or unrelenting (2). Despite this, there were nearly 25,000 in-hospital admissions to UK National Health Service hospitals (not including attendances to Emergency departments) in 2014-15 for epistaxis (3), accounting for more than £1.5 million in hospital bed costs alone, without factoring in the treatment costs (4). Emergency in-hospital interventions range from tamponade of the nasal cavity using nasal packs, cautery of bleeding vessels using chemicals or diathermy, or closing source arteries proximal to the bleeding point, using surgery or interventional radiology.

A recent suite of systematic reviews was undertaken by INTEGRATE (the National ENT Trainee Research Collaborative) to summarise the published evidence regarding the management of epistaxis (5-8). There was limited evidence to suggest an association between epistaxis and age (9,10), sustained ambulatory hypertension (11) and cardiovascular disease (12). Identified studies suggested that nasal packing (13,14), nasal cautery (13,15,16), antithrombotic medications (17), surgery (18) and trans-catheter arterial embolization (19) all affected rates of epistaxis control. In-hospital management of epistaxis frequently involves patients of varying grades of disease severity, who receive more than one treatment. To date studies of epistaxis interventions have been typically of small sample size (20) , and often of insufficient power to calculate the effect of any individual intervention, independent of disease severity and additional treatments received (21). Previous audits of epistaxis management have shown considerable variation in practice that may reflect the uncertainty inherent in the current evidence (22,23).

INTEGRATE, the UK ENT Trainee Research Network, recently undertook the largest prospective audit of adult inpatient epistaxis management to date, collecting data on more than 1200 cases across the United Kingdom over a 30-day observation window. Data captured included potential patient risk factors, interventions received during in-hospital

care, treatment success and 30-day re-admission data(24). Using this large and rich dataset, we aimed to investigate the role of different treatments and management strategies on successful in-hospital management of epistaxis. We analysed the role of initial interventions on overall treatment success, independent of subsequent treatments, patient factors and disease severity, and assessed the extent to which management strategies followed new guidelines (25), and the effect of this had on patient outcome.

## Methods

### Ethical approval

NHS Research Ethics Committee guidance was sought regarding the use of the national audit dataset beyond a simple comparison against identified audit standards. Completion of the Health Research Authority Guidance Tool confirmed that formal NHS Research Ethics Committee approval was not required.

### Design

Secondary analysis was performed on the dataset produced from a national audit of epistaxis management in adults (Cohort design). The pilot (22), final audit methods and preliminary results (24) have been described previously.

### Interventions analysed

The impact of interventions was assessed in two ways. First, the type of initial intervention received by a patient (following assessment and supportive measures) was categorised as; cautery, intranasal packing, surgery, radiological embolisation or a combination of these. The effect of intervention type on outcome was assessed.

Secondly, since the sequence of individual interventions undertaken during the whole admission would have been difficult to model and interpret, the effect of the overall management strategy during inpatient admission was investigated. Based on national consensus recommendations, endorsed by the British Rhinological Society (BRS) and ENT-UK(25), we evaluated each patient's management strategy (chronological order of interventions instigated during the hospital stay) to identify whether their management had

followed national recommendations (guidance compliant) or not (guidance non-compliant). Management strategies that were considered compliant with national guidelines are listed in the supplementary material. Two ENT surgeons (NM and RW), independently reviewed each patients' management strategy to assess whether interventions had been undertaken in a chronological sequence that complied with national recommendations. Cases assessed differently by reviewers were discussed individually until consensus was reached. Where consensus could not be reached cases were referred to a senior surgeon (CH).

## Outcomes

Two outcomes were selected:

1. Treatment time (time from first ENT review to the point when haemostasis was achieved – i.e. the point at which the ENT team decided that the epistaxis had been resolved, and the patient was safe for hospital discharge). It excluded the time it took for the patient to be seen and treated in the Emergency Room, and the time it took for the patient to actually leave the hospital, which was occasionally delayed due to administrative or social issues.
2. Hospital re-attendance rate with recurrent epistaxis within 30 days of discharge. This only included patients who re-attended under the ENT team for epistaxis. It did not include those who may have been successfully treated for recurrence through self-care or their local primary and emergency care teams.

These outcomes were chosen as they reflected both the early and longer-term efficacy of interventions, and they were readily extractable from the dataset available.

## Data Cleaning

Data set cleaning was performed by statisticians (JC, BJ and KS), and any queries were dealt with by clinicians on the steering committee (NM, RW and MS). Data was included if the observation was within the audit period, was not a duplicate entry, and contained valid treatment times. A clinician scrutinised all participants with a treatment time of zero. If the

clinician determined the treatment time of zero was invalid, treatment time was replaced with a suitable proxy; either discharge time or the last recorded time intervention.

## Statistical Analysis

The statistical analysis was performed in three stages: i) identify which ENT initial individual interventions (intervention at first ENT review e.g. nasal cautery VERSUS nasal packing etc.) were associated with the treatment time for each case; ii) identify which intervention strategies (sequence of all interventions instigated throughout admission e.g. nasal packing then nasal cautery VERSUS nasal cautery then nasal packing, etc.) were associated with improved time to achieve haemostasis; and iii) identify which individual interventions and intervention strategies were associated with 30-day re-attendance to ENT. All statistical analyses were conducted in R statistical package (version 3.4.2)(26).

## Initial ENT (Individual) Interventions

Exploratory analysis of the data was performed first to identify potential patient factors and individual interventions given at first ENT review that justified subsequent further inferential analysis via statistical models. In addition, a series of systematic reviews developed for the project (5-8) were also used to identify any additional potential associations. A full list of the patient factors investigated can be found in table 1.

Treatment time by patient characteristics and individual interventions was summarised using the geometric mean and corresponding 95% confidence interval (CI). If the confidence intervals of mean treatment time overlapped within variable outcomes (e.g. mean treatment time for patients with hypertension overlapped with mean treatment time for patients without hypertension) then these variables were not tested for inclusion in the model, unless stated *a priori*.

Approximately 60% of patients were successfully treated within 24 hours, and the remaining 40% took between 1 and 7 days to achieve definitive management, resulting in a highly skewed distribution of treatment time. For this reason, analysis of initial individual interventions and treatment time was performed using linear regression on the log



transformed treatment time. It was decided *a priori* to adjust the models for age, bleed severity (via World Health Organization (WHO) bleeding severity grade) (27) and Modified Early Warning Score (MEWS)(28), regardless of their statistical significance. Forward model selection was used to identify the interventions and any additional patient characteristics associated with treatment time, and these were included in the model if a goodness-of-fit test yielded a p-value <0.05. We tested for interactions between different factors, but statistical evidence only supported the inclusion of one interaction, the initial intervention (packing or cauterisation) and whether further interventions were required.

We performed sensitivity analysis (see supplementary material) to compare the differences between those who only required the initial interventions at their first ENT review with those who needed further interventions, by removing censored observations (i.e. removing those cases assigned proxy treatment times), and by WHO bleeding severity grade.

Evidence from the exploratory analysis suggested that some categories of factors could be merged. The categories were combined once a clinician confirmed that the new categories remained clinically valid. Full details of the exploratory analysis have been previously published(24), including further detail, plots and summary statistics calculated from the Epistaxis audit.

Due to the large number of factors to be investigated, we used forward model selection, and a factor was included in the model if there was evidence at the 5% significance level that the factor was contributing to the model. As more than 67% of patients required additional treatment after their first intervention, the log linear model for treatment time was adjusted for additional treatment performed after the first intervention, age, sex and markers of disease severity such as WHO bleeding severity grade (WHO grade 1 epistaxis <30 minutes within 24 hours, grade 2 epistaxis >30minutes within 24 hours, grade 3 epistaxis severe enough to require blood transfusion)(27) and Modified Early Warning Score (MEWS is scored 0-3 based on systolic blood pressure, heart rate, respiratory rate, temperature and AVPU scales) (28). As there appeared to be two sub-populations of patients admitted with epistaxis – those successfully treated within 24 hours and those that required several ENT interventions - it was important to insure patient factors were

significantly related to treatment time across the entire population. Therefore, sensitivity analyses were performed to determine if the factor effect size remained consistent if patients with censored treatment time were excluded (e.g. Is WHO bleeding score related to treatment times in patients successfully treated within 24 hours as well as those that needed several interventions?)

#### *Intervention Strategy*

The sequence of interventions performed on each patient was used to determine whether the sequence followed the BRS epistaxis guidelines or not.

Kaplan-Meier curves with 95% CI were used to explore the association between treatment time and the two distinct intervention strategies (guidance compliant and guidance non-compliant), and patient factors. If CIs overlapped, further analysis was not performed as it was unlikely that there would be a statistically significant difference in the success of these different management strategies.

To evaluate potential a relationship between intervention strategies and treatment time, a cox proportional hazard model was fitted to the data. It was decided to adjust the model for age, WHO bleeding severity grade and MEWS *a priori*.

#### *Re-attendance to ENT*

Factors potentially associated with re-attendance were identified via comparison of percentage 30-day re-attendance rate. If there was a difference >10% in re-attendance rate between groups characterised by the presence or absence of a certain factor, these factors were selected for further investigation. A difference of 10% was selected because the 95% CI for a percentage calculated from 100 observations is approximately  $\pm 10\%$ , therefore differences less than this value were unlikely to be statistically significant.

To identify factors associated with 30-day ENT re-attendance we fitted logistic regression models to the data. Forward selection was used to identify associated factors, and only

included if the goodness of fit p-value was <0.05. As with the previous models, it was decided *a priori* to adjust for age, WHO bleeding severity grade and MEWS.

Results relating to the initial ENT (individual) intervention are presented as adjusted ratios (aR), which demonstrate the difference in treatment time between individual levels of a factor on a multiplicative scale, after adjusting for markers of disease severity (WHO grade and MEWS) and age. For example, if examining the role of initial ENT intervention X showed an aR of 2, it would mean that intervention X increased treatment time two-fold, even after controlling for disease severity and age, when compared to those who did not receive factor X. A censored time-to-event analysis was used to assess the association between guidance compliant intervention strategies and the treatment time.

Results relating to intervention strategy are presented as adjusted hazard ratio (aHR), which demonstrate risk in relation to a timescale, on a multiplicative scale. For example, if examining the role of intervention strategy Z showed an aHR of 2, the result is best interpreted as patients receiving intervention strategy Z achieved haemostasis 66% faster than those that did not.

## Results

The audit data set consisted of a total of 1826 entries recorded from 116 sites during the audit window. During data cleaning 305 entries were removed as duplicates, 89 were found to lie outside the audit period, and 30 patients were successfully treated prior to management by ENT. 280 patients had insufficient data to allow treatment times to be calculated (time of first ENT review or time of treatment completion) and 288 patients had incomplete data on key patient variables – described below- and were thus excluded from analyses of treatment time(n=834). 197 patients had insufficient data on ENT re-attendance and 417 had missing data on key patient variables – described below - and were thus excluded from analyses of re-attendance rate (n=788)(Figure 1 shows the number of patients who were included in the analysis). Patient data sets were incomplete for the following reasons; 25% of patients had no MEWS recorded, 20% had treatment time missing or invalid and 14% had missing re-admission data.

299

300 Table 1 and 2 contains the summary statistics of factors previously linked to treatment time,  
 301 and those new factors with evidence suggesting a significant association with treatment  
 302 time, for the entire dataset. When removing the observations with censored data (I.e  
 303 patients successfully treated following one ENT review), there was little to no difference in  
 304 the ratios of times or the 95% CI in table 2 (see table 6 of supplementary material) justifying  
 305 use of the complete dataset.

306

### 307 [Effect of patient factors and specific interventions on treatment time](#)

308 Table 3 contains the adjusted treatment time ratios. The final model adjusted  $R^2$  value  
 309 indicated the model accounted for approximately 68.4% of the variation within the data.

310

311 There was no evidence of a statistical association between a patient's age or MEWS and  
 312 their treatment time. However, there was evidence of an association between treatment  
 313 time and WHO bleeding severity grade. The evidence indicated that as WHO grade  
 314 increased (i.e. bleed severity increased), treatment time also increased. Individuals with  
 315 WHO grade II bleeding were likely to have a treatment time 1.3 times those with grade 1  
 316 (30% longer). Those with grade III bleeding were likely to have a treatment time 2.2 times  
 317 those with a grade I.

318

319 There was evidence to suggest that the choice of intervention given at the first review may  
 320 have been dependent on the WHO grade. Evidence showed that as WHO grade increased,  
 321 so did the proportion of individuals who were packed, but as WHO grade increased the  
 322 proportion of those cauterised decreased. Therefore, it was considered essential to control  
 323 for WHO bleeding severity score in the final model, to assess the impact of initial treatment  
 324 independent of bleeding severity.

325

326 From the analysis of initial ENT individual intervention to treatment time (see table 3), it can  
 327 be seen that patients who were cauterised at first ENT review had 60% reduction in  
 328 treatment time compared to those who were not cauterised (Adjusted ratio 0.4, 95%CI 0.3 –  
 329 0.6), but individuals who were packed had a treatment time seven times longer than those  
 330 who were not packed (Adjusted Ratio 7.1, 95%CI 4.3 – 11.7). This data represents the effect

of initial treatments after controlling for bleeding severity. However, if initial treatments were not successful and another review was required, the effect of cautery diminished substantially. The plot in figure 2 is an example to demonstrate how different initial ENT-instigated treatments affected treatment times for a patient who was <65 years, with a WHO grade of II and MEWS of 1. Additionally, this plot demonstrates that attempting cauterisation initially, even when unsuccessful, does not increase treatment time.

#### Effect of intervention strategy on treatment time

Analysis of different intervention strategies on treatment time were conducted via Kaplan-Meier estimates, as shown in Figure 3. There was no evidence of an association between either age or MEWS with treatment times within Cox's proportional hazard model, but strong evidence of an association between treatment time and WHO bleeding severity score. The Kaplan-Meier plots showed how treatment time was less for those with a lower grade score. Patients treated with a guideline-compliant management strategy had a shorter treatment time, indicated by the Kaplan-Meier estimates with no over-lap of the 95% CIs, suggesting a statistically significant effect size. Whilst the Kaplan-Meier plot indicates that the difference was substantial, it this did not control for patient age, MEWS or WHO bleeding severity grade. This association was explored using the multi-variable Cox model, Table 4, which showed that even after controlling for age and WHO grade, the hazard ratio was 6.8 (5.7-8.8). This indicated that those managed in a guideline compliant manner were seven times more likely to be successfully treated at any time point than those who were not. In real terms this means that patients who received treatments according to national guidelines were 87% more likely to be successfully treated before those who received treatments that did not follow national guidelines ( $HR/(1+HR)$ = odds of first success - (29)). The significance of the effect of WHO bleeding severity grade on treatment time indicated that those with a lower grade had a faster treatment time than those with a higher grade.

#### Factors influencing 30-day re-admission

Eighty-eight (8.9%) patients were re-admitted to ENT within 30 days of presentation. There was no significant association between re-admission and type of intervention received

during hospital treatment. The only statistically significant predictor of re-admission to ENT was a history of epistaxis in the preceding 12 months (Table 4), which more than doubled the risk of re-admission.

## Discussion

### Summary

The type of initial individual intervention provided to patients with epistaxis at first review by an ENT specialist significantly affects overall treatment time, even after controlling for disease severity and subsequent interventions. Patients who received only nasal packing as their first specialist treatment took 7.1 times longer to reach haemostasis than those who were not packed. Patients that were not cauterised at first review required 2.5 times more treatment time compared to those that were. This result holds even after controlling for bleeding severity as stratified by WHO bleeding score, the only factor found to influence treatment time. Our results suggest that attempting nasal cautery reduces treatment time if successful and doesn't increase treatment time if not successful. Initial intervention choice does not appear to have a significant impact on 30-day ENT re-attendance. Patients who received interventions in line with national guidelines were 87% more likely to successfully achieve haemostasis before those that did not.

Equally interesting are the negative results. The majority of cases of were managed by junior doctors (usually less than 18 months of ENT experience), but the grade of treating doctor did not affect the outcome in terms of treatment time or re-ttendance rate. The majority of patients had hypertension (55.4%) or were taking anti-thrombotics (57.1%), but the presence of these factors did not have an impact on treatment time or re-attendance either.

### Our findings in the context of the available literature

A previous smaller audit of in-hospital epistaxis management across six sites demonstrated similar mean length of stay(23), but due to the limited sample size inferential analysis could not be undertaken. Whilst there have been studies that have suggested worse treatment

outcomes for patients with ischaemic heart disease (12), hypertension (11), diabetes (17) and the use of antithrombotics(17), our study shows that once admitted to hospital and the severity of epistaxis is accounted for, these factors do not seem to affect treatment outcomes. The reason for the difference may be that these studies included smaller numbers, collected data retrospectively through case notes and defined success as not representing to hospital within two weeks of treatment.

Our study shows no difference in recurrence up to 30 days after hospital discharge, whether patients were cauterised or packed at first specialist review. Contradicting these findings, a retrospective audit on more than 300 adults with epistaxis attending a Canadian emergency room (30) showed reduced 14-day recurrence in patients who were cauterised compared to packed. However, nasal packing in the emergency room frequently requires re-attendance to remove the pack, and so this retrospective study may have misclassified re-attendance to remove pack with re-attendance to treat recurring epistaxis. Additionally, the case-mix of patients is unlikely to be comparable since our cohort only included those that had failed emergency room treatment, and probably represent those with more severe epistaxis.

### Strengths and weaknesses

This is the largest prospective study of in-hospital epistaxis management to date, with sufficiently detailed information to allow assessment of interventions and management strategy after controlling for patient (age, co-morbidities), disease (severity of bleeding) and treatment factors (grade of doctor and other therapies initiated). Our statistical strategy allowed us to better understand treatment effects by focusing on initial intervention and the overall management strategy (temporal sequence of treatments initiated). However, whilst our results suggest that cauterisation at initial ENT review reduces overall treatment time, irrespective of bleeding severity, care must be taken since bleeding severity was assessed by the WHO bleeding score. WHO bleeding score provided a convenient method by which to categorise bleed severity, but in practice it might prove difficult to stratify patients' interventions by this score alone. Unfortunately, it seems the MEWS was not sensitive enough to identify differences in the bleed severity of a patient, potentially

indicating that further work for a more tailored grading system for bleed severity is required.

There were only 88 patients who re-attended to ENT for epistaxis. As mentioned earlier, we estimated differences between groups would have to be approximately 10% to be statistically significant when comparing proportion between two groups. Therefore, it is a highly probable that this data lacks the sensitivity to detect clinically important differences that are less than 10%.

### Implications for future research and policy

Whilst these analyses suggest an increased role for nasal cautery at first specialist review, it must be noted that cautery can cause severe complications (31), and enforcing nasal cautery upon an inexperienced practitioner (87% of the patients were seen by junior doctors) may increase complication rates. On the other hand, 23% of patients that had a pack inserted in the emergency department had their pack removed for an examination when first reviewed by ENT, and only 30% of those with no packs had cautery attempted. This suggests there may be a culture or system in place that encourages rapid arrest of the epistaxis with nasal packing rather than deliberated nasal examination to assess for bleeding point. This may relate to the availability of expertise and or equipment. Further studies would help investigate the issues surrounding the reasons for the choice of intervention in more detail.

Whilst INTEGRATE and the BRS developed national guidelines to help align treatment pathways with best available evidence, these guidelines were not widely publicised prior to the national audit. However, they were drawn up to reflect a logical sequence of interventions based on widely available evidence, and so it is surprising that only 30% of patients received treatments that followed an evidence-based course. Whilst treatment pathways should be adapted to the resource availability of local departments, there is clear evidence from our analyses that following national guidance can reduce treatment time without compromising 30-day re-attendance, and local departments should be encouraged to adapt their resources to better comply with these guidelines.



453

454 Trainees collaborated nationally to deliver the largest study of inpatient epistaxis  
455 management to date, designing and leading research into a condition that has a large  
456 disease burden. Undertaking this study has not only highlighted new evidence relating to  
457 epistaxis, but it has encouraged the new generation of surgeons to better appreciate  
458 research as a common tool to resolve critical clinical problems.

459

460

461

462


## References

1. Cummings CW, Paul W Flint MD, Harker LA, Bruce H Haughey MD. Cummings Otolaryngology. Mosby Incorporated; 2004. 1 p.
2. Douglas R, Wormald P-J. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg. 2007 Jun;15(3):180–3.
3. HESonline.  
costing-statement-2187244909.
5. Khan M, Conroy K, Ubayasiri K, Constable J, Smith ME, Williams RJ, et al. Initial assessment in the management of adult epistaxis: systematic review. J Laryngol Otol. Cambridge University Press; 2017 Dec 1;131(12):1035–55.
6. Iqbal IZ, Jones GH, Dawe N, Mamais C, Smith ME, Williams RJ, et al. Intranasal packs and haemostatic agents for the management of adult epistaxis: systematic review. J Laryngol Otol. Cambridge University Press; 2017 Dec 27;131(12):1065–92.
7. Swords C, Patel A, Smith ME, Williams RJ, Kuhn I, Hopkins C. Surgical and interventional radiological management of adult epistaxis: systematic review. J Laryngol Otol. Cambridge University Press; 2017 Dec 27;131(12):1108–30.
8. Williams A, Biffen A, Pilkington N, Arrick L, Williams RJ, Smith ME, et al. Haematological factors in the management of adult epistaxis: systematic review. J Laryngol Otol. Cambridge University Press; 2017 Dec 27;131(12):1093–107.
9. Pallin DJ, Chng Y-M, McKay MP, Emond JA, Pelletier AJ, Camargo CA. Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann Emerg Med. 2005 Jul;46(1):77–81.
10. Seidel DU, Jacob L, Kostev K, Sesterhenn AM. Risk factors for epistaxis in patients followed in general practices in Germany. Rhinology. 2017 Dec 1;55(4):312–8.
11. Min HJ, Kang H, Choi GJ, Kim KS. Association between Hypertension and Epistaxis: Systematic Review and Meta-analysis. Otolaryngology-Head and Neck Surgery. SAGE PublicationsSage CA: Los Angeles, CA; 2017 Jul 25;157(6):921–7.
12. Côte FC, Orfao T, Dias CC, Moura CP, Santos M. Risk factors for the occurrence of epistaxis: Prospective study. Auris Nasus Larynx. Elsevier; 2017 Aug 24.
13. Ha JF, Hodge JC, Lewis R. Comparison of nasendoscopic-assisted cautery versus packing for the treatment of epistaxis. ANZ J Surg. Blackwell Publishing Asia; 2011 May;81(5):336–9.

- 502 14. Murray S, Mendez A, Hopkins A, El-Hakim H, Jeffery CC, Côté DWJ.  
503 Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs.  
504 traditional nasal packing: a prospective randomized control trial. J  
505 Otolaryngol Head Neck Surg. BioMed Central; 2018 Dec 1;47(1):3.
- 506 15. Mudunuri RKR, Murthy MAN. The Treatment of Spontaneous Epistaxis:  
507 Conservative vs Cautery. J Clin Diagn Res. 2012 Nov;6(9):1523–4.
- 508 16. Murthy P, Nilssen EL, Rao S, McClymont LG. A randomised clinical trial  
509 of antiseptic nasal carrier cream and silver nitrate cautery in the treatment  
510 of recurrent anterior epistaxis. Clin Otolaryngol Allied Sci. 1999  
511 Jun;24(3):228–31.
- 512 17. Abrich V, Brozek A, Boyle TR, Chyou P-H, Yale SH. Risk factors for  
513 recurrent spontaneous epistaxis. Mayo Clin Proc. 2014 Dec;89(12):1636–  
514 43.
- 515 18. Asanau A, Timoshenko AP, Vercherin P, Martin C, Prades J-M.  
516 Sphenopalatine and anterior ethmoidal artery ligation for severe  
517 epistaxis. Ann Otol Rhinol Laryngol. 2009 Sep;118(9):639–44.
- 518 19. Dubel GJ, Ahn SH, Soares GM. Transcatheter embolization in the  
519 management of epistaxis. Semin Intervent Radiol. Thieme Medical  
520 Publishers; 2013 Sep;30(3):249–62.
- 521 20. Ando Y, Iimura J, Arai S, Arai C, Komori M, Tsuyumu M, et al. Risk  
522 factors for recurrent epistaxis: Importance of initial treatment. Auris Nasus  
523 Larynx. Elsevier; 2014 Feb 1;41(1):41–5.
- 524 21. Knofczynski GT, Mundfrom D. Sample Sizes When Using Multiple Linear  
525 Regression for Prediction. Educational and Psychological Measurement.  
526 3rd ed. SAGE PublicationsSage CA: Los Angeles, CA; 2007 Nov  
527 9;68(3):431–42.
- 528 22. Mehta N, Williams RJ, Smith ME, Hall A, Hardman JC, Cheung L, et al.  
529 Can trainees design and deliver a national audit of epistaxis  
530 management? A pilot of a secure web-based audit tool and research  
531 trainee collaborati... - PubMed - NCBI. ncbinlmnihgov. Cambridge  
532 University Press; 2017 Mar 23;131(06):518–22.
- 533 23. Hall AC, Blanchford H, Chatrath P, Hopkins C. A multi-centre audit of  
534 epistaxis management in England: is there a case for a national review of  
535 practice? J Laryngol Otol. 2015 May;129(5):454–7.
- 536 24. INTEGRATE (The National ENT Trainee Research Network). Epistaxis  
537 2016: national audit of management. J Laryngol Otol. Cambridge  
538 University Press; 2017 Dec;131(12):1131–41.
- 539 25. INTEGRATE (The National ENT Trainee Research Network). The British  
540 Rhinological Society multidisciplinary consensus recommendations on  
541 the hospital management of epistaxis. Cambridge University Press; 2017.  
542 pp. 1142–56.


26. December RTUHW-POA, 2013. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.[WWW document].
27. Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of  $10 \times 10^9$  per L versus  $30 \times 10^9$  per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion. Blackwell Science Inc; 2005 Jul 1;45(7):1064–72.
28. Stenhouse C, Coates S, Tivey M, Allsop P, Parker T. Prospective evaluation of a modified Early Warning Score to aid earlier detection of patients developing critical illness on a general surgical ward. British Journal of Anaesthesia. 2000 May;84(5):663P.
29. Spruance SL, Reid JE, Grace M, Samore M. Hazard Ratio in Clinical Trials. Antimicrob Agents Chemother. 2004 Jul 23;48(8):2787–92.
30. Newton E, Lasso A, Petrcich W, Kilty SJ. An outcomes analysis of anterior epistaxis management in the emergency department. J Otolaryngol Head Neck Surg. BioMed Central; 2016 Apr 11;45(1):24.
31. Murthy P, Laing MR. An unusual, severe adverse reaction to silver nitrate cautery for epistaxis in an immunocompromised patient. Rhinology. 1996 Sep;34(3):186–7.

## Tables and Figures



*Figure 1 Data analysis flow chart This figure shows how data was entered onto a central database and the results of subsequent data cleaning led to different sample sizes for 3 different analyses. Patient data were initially excluded if it did*

568 not meet inclusion criteria, or was duplicated (424 entries excluded). Further data were excluded due to missingness in  
569 variables that were considered essential for each of the three analyses.



570  
571

572 *Figure 2: Expected treatment time with 95% confidence intervals of patients by cauterisation status: successful (dark green*  
573 *square and light green bars); failed (red circle with orange dashed bars); not cauterised (blue triangle with light blue dotted*  
574 *bars) and packing status (not packed or packed) at first ENT review. This graphic demonstrates that cauterising reduces*  
575 *treatment time if successful but does not change treatment time if unsuccessful. Additionally, those who are packed have*  
576 *the longest treatment times of all treatment arms.*  
577

### Kaplan-Meier Estimate of Time to Achieve Haemostasis




Figure 3: Kaplan-Meier estimates and 95% confidence intervals of treatment time by intervention strategy: guideline compliant (dark green line and 95% CI shaded in light green) and non-compliant (blue dashed line with 95% CI shaded in light blue). This graph shows that when treatment follows national guidance treatment time reduces significantly.

	N (%)			Treatment Time in hrs Mean (95% CI) <sup>1</sup> [Range]
	Total	No Re- Admission 896 (91.1)	30-day Re- Admission 88 (8.9)	
Age Group in years:				
• < 65	325 (29.0)	261 (90.0)	29 (10.0)	7.0 (5.6, 8.9) [0.0 – 152.3]
• 65 ≤ Age < 75	278 (24.8)	223 (91.0)	29 (9.0)	6.2 (4.9, 7.9) [0.0 – 114.9]
• 75 ≤ Age < 85	313 (28.0)	248 (92.5)	20 (7.5)	9.0 (7.2, 11.1) [0.0 – 109.0]
• ≥ 85	203 (18.1)	162 (90.5)	17 (9.5)	5.5 (4.2, 17.8) [0.1 – 144.6]
Gender:				

• Female	492 (43.9)	394 (91.0)	39 (9.0)	6.2 (5.1, 7.4) [0.0 – 144.6]
• Male	630 (56.1)	502 (91.1)	49 (8.9)	7.6 (6.5, 8.9) [0.0 – 152.3]
WHO				
• Grade I	143 (12.8)	96 (90.6)	10 (9.4)	2.0 (1.4, 2.9) [0 – 104.0]
• Grade II	922 (82.7)	758 (91.7)	69 (7.8)	7.8 (6.8, 8.8) [0.0 – 143.2]
• Grade III	50 (4.5)	36 (81.8)	8 (18.2)	28.7 (19.3, 44.9) [0.2 – 152.3]
MEWS				
• 0	232 (27.6)	196 (90.7)	20 (9.3)	7.0 (5.4, 9.1) [0.0 – 118.4]
• 1	307 (36.5)	248 (90.7)	21 (7.8)	7.2 (5.7, 9.1) [0.0 – 116.4]
• 2	150 (17.8)	113 (89.0)	14 (11.0)	8.3 (6.2, 11.3) [0.2 – 152.3]
• 3	93 (11.1)	75 (88.2)	10 (11.8)	10.0 (6.9, 14.6) [0.1 – 104.0]
• ≥ 4	59 (7.0)	55 (100.0)	0 (0.0)	14.0 (9.4, 21.0) [0.3 – 109.0]
Diabetes				
• No	930 (85.6)	751 (92.3)	63 (7.7)	6.9 (6.0, 7.9) [0.0 – 143.2]
• Yes	156 (14.4)	119 (85.0)	21 (15.0)	8.9 (6.5, 12.1) [0.0 – 152.3]
Hypertension				
• No	498 (44.6)	369 (91.0)	39 (9.0)	5.5 (4.6, 6.7) [0.0 – 143.2]
• Yes	618 (55.4)	495 (91.0)	49 (9.0)	8.3 (7.1, 9.7) [0.0 – 152.3]
Heart Disease				
• No	762 (69.6)	611 (91.6)	56 (8.4)	6.6 (5.7, 7.6) [0.0 – 143.2]
• Yes	333 (30.4)	267 (90.5)	28 (9.5)	8.8 (7.1, 10.9) [0.0-152.3]
Previous Epistaxis				
• No	808 (74.0)	661 (93.1)	49 (6.9)	6.5 (5.6, 7.5) [0.0 – 130.6]]
• Yes	284 (26.0)	207 (84.1)	39 (15.9)	8.5 (5.7, 10.7) [0.0 – 152.3]
Antithrombotic				
• No	475 (42.9)	367 (89.5)	43 (10.5)	6.0 (5.0, 7.3) [0.0 – 143.2]
• Yes	631 (57.1)	514 (91.9)	45 (8.1)	7.9 (6.7, 9.2) [0.0 – 152.3]

Table 1: Summary statistics of 30-day readmission and treatment time by patient's medical history. This is extracted from the raw dataset. Analysis was done on a subset who had sufficient data regarding outcomes for analysis and therefore final analysis is only on 834 patients. <sup>1</sup> Geometric mean and 95% CI

588

589

	N (%)			Treatment Time in hrs Mean (95% CI) <sup>1</sup> [Range]
	Total	No Re- Admission 896 (91.1)	30-day Re- Admission 88 (8.9)	
Packed at ED				
• No	605 (53.9)	469 (90.7)	48 (9.3)	3.4 (2.8, 4.0) [0.0 – 144.6]
• Yes	517 (46.1)	427 (91.4)	40 (8.6)	16.2 (14.2, 18.4) [0.0 – 152.3]
Cauterised at 1 <sup>st</sup> ENT review				
• No	757 (67.5)	600 (90.9)	60 (9.1)	17.1 (15.4, 18.9) [0.0 – 152.3]
• Yes	365 (32.5)	296 (91.4)	28 (8.6)	1.1 (0.9, 1.3) [0.0 – 116.4]
Packed at 1 <sup>st</sup> ENT				
• No <sup>2</sup>	443 (39.5)	345 (90.6)	551 (9.4)	1.1 (0.9, 1.3) [0.0 – 104.0]
• Yes	679 (60.5)	551(91.4)	52 (8.6)	23.0 (21.2, 24.9) [0.0 – 152.3]
Dr Grade at 1 <sup>st</sup> ENT				
• Nurse	38 (3.5)	34 (91.9)	3 (8.1)	2.3 (1.2, 4.5) [0.2 – 63.7]
• Junior	950 (86.6)	751 (91.4)	71 (8.6)	7.3 (6.5, 8.4) [0.0 – 152.3]
• Middle	101 (9.2)	84 (87.5)	12 (12.5)	8.5 (5.8, 12.5) [0.0 – 109.0]
• Consultant	8 (0.7)	6 (85.7)	1 (14.3)	3.2 (0.7, 14.1) [0.3 – 42.8]
Interventions after 1 <sup>st</sup> ENT				
• No	365 (62.5)	288 (91.7)	26 (8.3)	0.7 (0.6, 0.8) [0.0 – 26.0]
• Yes	757 (67.5)	608 (90.7)	62 (9.3)	21.2 (19.5, 23.0) [0.0 – 152.3]
Surgery				



• No	1080 (96.9)	866 (91.4)	81 (8.6)	6.5 (5.8, 7.4) [0.0 – 152.3]
• Yes	35 (3.1)	24 (80.0)	6 (20.0)	42.1 (32.9, 54.0) [8.8 – 144.6]
Intervention Strategy				
• Compliant	334 (29.8)	626 (91.0)	62 (9.0)	0.7 (0.6, 0.9) [0.0 – 50.5]
• Non-compliant	788 (70.2)	270 (91.2)	26 (8.8)	18.1 (16.4, 19.9) [0.0 – 152.3]

<sup>1</sup> Geometric mean and 95% CI

<sup>2</sup> Includes those whose ED pack was removed

Table 2: Summary statistics of 30-day re-admission and treatment time by patient's Epistaxis management.

Factor	Adjusted Ratio (95% CI) <sup>2</sup>	p-value
Packed at first ENT review		
No	1	-
Yes	7.1 (4.3 – 11.7)	< 0.001
Cauterised at first ENT review		
No	1	-
Yes	0.4 (0.3 – 0.6)	< 0.001

<sup>1</sup> Summary statistics for patients with complete model data

<sup>2</sup> Adjusted for severity scores (MEWS and WHO), age and subsequent treatment after the initial ENT review.

Table 3: Initial ENT treatments and their effect on overall treatment time. Table of the number (N) and percentage of total within each variable category; the median and Interquartile range of treatment time in hours; and the ratio and 95% confidence intervals.

Factor	Adjusted Hazard Ratio (95% CI)	p-value
Guideline compliant		
No	1	-
Yes	6.8 (5.7, 8.2)	< 0.001
Age Group		
< 65	1	-
65 ≤ Age < 75	1.1 (0.9, 1.3)	0.3
75 ≤ Age < 85	0.9 (0.7, 1.0)	0.1
≥ 85	1.2 (1.0, 1.5)	0.04
MEWS		
0	1	-

	1	0.9 (0.7, 1.1)	0.2
	2	1.0 (0.8, 1.2)	0.8
	3	0.9 (0.7, 1.2)	0.6
	≥ 4	1.0 (1.0, 1.5)	0.8
WHO Grade	I	1	-
	II	0.8 (0.6, 1.0)	0.02
	III	0.3 (0.2, 0.5)	< 0.001

<sup>1</sup> Summary statistics are for patients with complete model data

<sup>2</sup> Adjusted for severity scores (MEWS and WHO) and age.

Table 4: Adjusted Cox's proportional hazards model of time to achieve haemostasis by intervention strategy.

Factor	Adjusted Odds Ratio (95% CI) <sup>1</sup>	p-value
History of Epistaxis No	1	-
Yes	2.4 (1.4 – 3.9)	0.001

<sup>1</sup> Adjusted for severity scores (MEWS and WHO) and age.

Table 5: Role of Initial ENT treatment and admission patient and disease characteristics on 30-day epistaxis related ENT re-admission.

## Supplementary material

	Adjusted Ratio (95% CI)	p-value
Sensitivity Analysis 1		
Packed at first ENT review No	1	-
Yes	7.0 (4.3 - 11.8)	< 0.001
Cauterised at first ENT review No	1	-
Yes	0.4 (0.3 – 0.6)	< 0.001
Sensitivity Analysis 2		
Packed at first ENT review No	1	-
Yes	7.5 (4.5 – 12.5)	< 0.001
Cauterised at first ENT review No	1	-
Yes	0.5 (0.3 – 0.7)	< 0.001
Sensitivity Analysis 3		
Packed at first ENT review No	1	-

Cauterised at first ENT review	Yes	2.3 (1.8 – 3.0)	< 0.001
	No	1	-
	Yes	0.9 (0.7 – 1.2)	0.59

Table 6: Sensitivity Analysis 1: log linear regression model removing censored observations. Sensitivity Analysis 1: log linear regression model of patients who did not require further interventions after their initial ENT intervention. Sensitivity Analysis 1: log linear regression model of observations who required further interventions after their initial ENT intervention.

### Kaplan-Meier Estimate of Time to Achieve Haemostasis




Figure 4: Kaplan-Meier estimates and 95% confidence intervals of treatment time by WHO bleeding grade: WHO I (blue dashed line with 95% CI shaded in light blue); WHO II (dark green line and 95% CI shaded in light green); WHO III (dark red dotted line and 95% CI shaded in red)..




Figure 5 Derived epistaxis management steps based on BRS guidelines. The above flow chart shows the potential steps in managing a patient with epistaxis. These steps were adapted from BS epistaxis management guidance and each steps describes the subsequent treatment if previous has failed.

626

## 627 Contributors

628 Contributions

629 Author Committee

630 Nishchay Mehta (Corresponding Author) BSc PhD MBBS DOHNS FRCS (ORL-HNS), Royal  
631 National Throat Nose and Ear Hospital, 330 Gray's Inn Road, London, UK, 00447863545576,  
632 [Nishchay.mehta.12@ucl.ac.uk](mailto:Nishchay.mehta.12@ucl.ac.uk)

633 Kara Stevens BSc MSc MRes PhD, Medical Statistics, Faculty of Medicine and Dentistry,  
634 University of Plymouth

635 Matthew Edward Smith MA, MBBChir, Cambridge university hospitals NHS Foundation Trust

636 Richard J Williams

637 Matthew Ellis

638 John C Hardman

639 Professor Claire Hopkins, FRCS(ORL-HNS) DM, King's College, London

640

641 Steering Committee: Matthew Ellis, Andrew Hall, John Hardman, Nishchay Mehta, Matthew  
642 Edward Smith and Richard J Williams

643 Executive committee: Sean Carrie and Claire Hopkins.

644 Statisticians: Jade Chynoweth, Ben G Jones, Nishchay Mehta and Kara Stevens.

645 Site leads: Y. Abbas, Southend Hospital; M. Abdelkader, Basildon and Thurrock Hospital; M.

646 Adams, Altnagelvin; A. Addison, James Paget Hospital; R. Advani, North Manchester General

647 Hospital; T. Ahmed, Dorset County Hospital; V. Alexander, Brighton General Hospital; V.

648 Alexander, Royal Sussex County Hospital; B. Alli, Bradford Royal Infirmary; S. Alvi, Leighton

649 Hospital; N. Amiraraghi, Crosshouse Hospital; A. Ashman, The Great Western Hospital; R.

650 Balakumar, Gloucestershire Royal Hospital; J. Bewick, Addenbrookes Hospital; D. Bhasker,

651 Pinderfields General Hospital; S. Bola, Wexham Park Hospital; P. Bowles, Worthing Hospital;

652 N Campbell, Chesterfield Royal Hospital; N. Can Guru Naidu, Barnet Hospital; N. Caton, East

653 Surrey Hospital; J. Chapman, Salisbury District Hospital; G. Chawdhary, Milton Keynes

654 General Hospital; M. Cherko, John Radcliffe Hospital; M. Coates, Sunderland Royal Hospital;

655 K. Conroy, Wythenshawe Hospital, Macclesfield District General Hospital; P. Coyle,

656 Peterborough City Hospital; O. Cozar, University Hospital of North Staffordshire; M.

657 Cresswell, Derriford Hospital; L. Dalton, Arrowe Park; J. Danino, New Cross Hospital; C.  
658 Daultrey, Worcester Royal Hospital; K. Davies, Morriston Hospital; K. Davies, Royal Liverpool  
659 University Hospital; D. Dick, Royal Victoria Hospital; P. A. Dimitriadis, Royal Hallamshire  
660 Hospital; N. Doddi, Princess of Wales Hospital; M. Dowling, Stepping Hill Hospital; R. Easto,  
661 Monklands Hospital; r. edmiston, Royal Albert Edward Infirmary; D. Ellul, Western General  
662 Hospital; S. Erskine, West Suffolk Hospital; A. Evans, Barnsley District General Hospital; A.  
663 Farboud, University Hospital of Wales; C. Forde, King George Hospital; J. Fussey, Walsall  
664 Manor Hospital; A. Gaunt, Queens Medical Centre; J. Gilchrist, Royal Bolton Hospital; R.  
665 Gohil, New Royal Infirmary of Edinburgh; E. Gosnell, Royal Blackburn Hospital; D. Grech  
666 Marguerat, Royal Cornwall Hospital; R. Green, Ninewells Hospital; R. Grounds, Medway  
667 Hospital; A. Hall, Royal National TNE Hospital; J. Hardman, St. Marys Hospital; A. Harris,  
668 Royal Gwent Hospital; L. Harrison, Northampton General Hospital; R. Hone, Royal Surrey  
669 County Hospital; E. Hoskison, University Hospital of Coventry & Warwickshire; J. Howard,  
670 Wrexham Maelor Hospital; D. Ioannidis, Royal Hampshire County Hospital; I. Iqbal, Freeman  
671 Hospital; N. Janjua, Queen Alexandra Hospital; k. jolly, Russells Hall Hospital; S. Kamal, Poole  
672 Hospital; T. Kanzara, Countess of Chester; N. Keates, Torbay Hospital; A. Kelly, Antrim Area  
673 Hospital; H. Khan, Fairfield General Hospital; T. Korampalli, Rotherham District General  
674 Hospital; M. Kuet, Colchester General Hospital; P. Kulloo, Royal London Hospitals; R.  
675 Lakhani, St Georges Hospital; A. Lambert, Charing Cross Hospital; H Lancer, St Thomas  
676 Hospital; C. Leonard, Royal Belfast Hospital for Sick Children; G. Lloyd, Guys hospital; E.  
677 Lowe, Southampton General Hospital; J. Mair, Birmingham Heartlands Hospital; E.  
678 Maughan, University College Hospital London; T. Mayberry, Queen Elizabeth Hospital -  
679 University Hospitals Birmingham NHSFT; L. McCadden, Craigavon Area Hospital; F.  
680 McClenaghan, West Middlesex University Hospital; G. McKenzie, Hull Royal Infirmary, Castle  
681 Hill Hospital; R. Mcleod, West Wales Hospital; S. Meghji, Norfolk & Norwich University  
682 Hospital; M. Mian, Furness General Hospital; A. Millington, Ipswich Hospital NHS Trust; O.  
683 Mirza, Royal Preston Hospital; S. Mistry, Calderdale Royal Hospital; E. Molena, Frimley Park  
684 Hospital; J. Morris, Royal United Hospital; T. Myuran, Basildon Hospital, Princess Alexandra  
685 Hospital; A. Navaratnam, Northwick Park Hospital; E. Noon, Blackpool Victoria Hospital; O.  
686 Okonkwo, Salford Royal Hospital; B. Oremule, Royal Lancaster Hospital; L. Pabla, James Cook  
687 University Hospital; E. Papesch, Broomfield Hospital; V. Puranik, Ysbyty Gwynedd Hospital;  
688 R. Roplekar, Raigmore Hospital; E. Ross, Birmingham City Hospital; J Rudd, William Harvey

689 Hospital; E. Schechter, Luton & Dunstable Hospital; A. Senior, Midlands Treatment Centre  
690 (Burton); N. Sethi, Leeds General Infirmary; S. Sharma, Central Middlesex Hospital; R.  
691 Sharma, St Johns Hospital; F Shelton, Musgrove Park Hospital; Z. Sherazi, Tameside General  
692 Hospital; A. Tahir, Cumberland Infirmary; T. Tikka, Queen Elizabeth University Hospital; O.  
693 Tkachuk Hlinicanova, Glan Clwyd Hospital; K. To, Royal Hospital for Sick Children Edin; A Tse,  
694 Royal Oldham Hospital; E. Toll, Royal Devon & Exeter Hospital; K. Ubayasiri, Royal Derby  
695 Hospital; S. Unadkat, Whipps Cross University Hospital; N. Upile, University hospital of  
696 Aintree; A. Vijendren, Lister Hospital; H. Walijee, Alder Hey; M Wilkie, Warrington Hospital,  
697 R. Williams, Bristol Royal Infirmary; M. Williams, Darlington Memorial Hospital; G. Wilson,  
698 Leicester Royal Infirmary; W. Wong, York District Hospital; G. Wong, North Hampshire  
699 Hospital; C. Xie, Princess Royal University Hospital; A. Yao, Manchester Royal Infirmary; H.  
700 Zhang, Queens Hospital Romford;  
701